DexComDXCM +1.18%90 ROA % is 12.30% as of Mar. 2026, which is 117% above its 10-year median of 5.66. GuruFocus rates DXCM with a GF Score™ of 90/100 and a GF Value™ of $103.50 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, DexCom ranks better than 92.88% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. DexCom's annualizedNet Income for the quarter that ended in Mar. 2026 was $798 Mil.
DexCom's average Total Assets over the quarter that ended in Mar. 2026 was $6,487 Mil. Therefore, DexCom's annualized ROA % for the quarter that ended in Mar. 2026 was 12.30%.
The historical rank and industry rank for DexCom's ROA % or its related term are showing as below:
DXCM'
s ROA % Range Over the Past 10 Years
Min: -18.88 Med: 5.66 Max: 14.77
Current: 13.46
During the past 13 years, DexCom's highest ROA % was 14.77%. The lowest was -18.88%. And the median was 5.66%.
DXCM's ROA % is ranked better than 92.88% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs DXCM: 13.46
DexCom (NAS:DXCM) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
DexCom ROA % Related Terms
DexCom ROA % Historical Data
* Premium members only.
The historical data trend for DexCom's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, DexCom's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DexCom ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, DexCom's ROA % distribution charts can be found below:
* The bar in red indicates where DexCom's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
DexCom (DXCM) has a ROA % of 12.30% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on DexCom and its competitors. This is 117% above median its historical median of 5.66. According to the industry distribution chart, DexCom ranks #61 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 7.1%.
Is DexCom's ROA % too high?
DexCom's current ROA % of 12.30% is 117% above median its 10-year median of 5.66. The Medical Devices & Instruments industry median ROA % is 0.59. DexCom's value of 12.30% is 1984.7% above this industry median. Based on the distribution chart, DexCom ranks #61 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, DexCom has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DexCom's ROA % compare to GEHC and STE?
According to the Medical Devices & Instruments industry distribution chart, DexCom ranks #61 out of 857 companies for ROA %. This places DexCom in the top 7% of its industry — outperforming the majority of peers. The industry median ROA % is 0.59. DexCom's value of 12.30% is 1984.7% above this benchmark. While the company's 10-year median is 5.66 vs. the industry median of 0.59, DexCom has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DexCom's current ROA % of 12.30% is 1984.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on DexCom and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DexCom's current ROA % is 12.30%, which is 117% above median its own 10-year median of 5.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexCom stock overvalued right now?
Based on GuruFocus' analysis, DexCom (DXCM) is currently considered Significantly Undervalued. The stock's GF Value™ is $103.50, compared to a current price of $69.75 — trading 32.6% below its estimated fair value. The current ROA % is 12.30%, which is 117% above median its 10-year median of 5.66 and 1984.7% above the Medical Devices & Instruments industry median of 0.59. DexCom's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For DexCom (DXCM), the current ROA % is 12.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DexCom (DXCM) Overvalued in 2026?
Based on GuruFocus' analysis, DexCom stock appears to be undervalued.
The current stock price of $69.75 is trading 32.6% below its estimated GF Value™ of $103.50.
GuruFocus considers DexCom to be Significantly Undervalued.
Key valuation signals for DXCM:
ROA %: 12.30% (117% above median its 10-year median of 5.66)
GF Value™: $103.50 vs. price of $69.75 (32.6% below fair value)
Industry Position: 1984.7% above the Medical Devices & Instruments median (#61 of 857)
No single metric tells the full story. See the DXCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
90GF Score
Get the complete analysis for DXCM
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DXCM has been successfully added to your 
